The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with lower intensity therapy in TP53-mutated AML.
 
Tapan M. Kadia
Honoraria - Amgen; Jazz Pharmaceuticals; Novartis; Pfizer
Consulting or Advisory Role - Jazz Pharmaceuticals
 
Prajwal C. Boddu
No Relationships to Disclose
 
Farhad Ravandi
Honoraria - Amgen; Incyte; Karyopharm Therapeutics; Seagen; Sunesis Pharmaceuticals; Xencor
Consulting or Advisory Role - Amgen; ARIAD; Incyte; Karyopharm Therapeutics; Seagen; Sunesis Pharmaceuticals
Research Funding - Amgen; Bristol-Myers Squibb; Incyte; Seagen; Sunesis Pharmaceuticals; Xencor
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Gautam Borthakur
No Relationships to Disclose
 
Michael Andreeff
Stock and Other Ownership Interests - Aptose Biosciences
Research Funding - Abbvie/Genentech (Inst); Aptose Biosciences (Inst); Daiichi Sankyo (Inst)
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo
 
Elias Jabbour
Consulting or Advisory Role - Pfizer
Research Funding - Pfizer
 
Courtney Denton Dinardo
Honoraria - Agios; Daiichi Sankyo; Novartis
Research Funding - Abbvie; AGIOS; Celgene; Daiichi Sankyo; Novartis
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Naval Guastad Daver
Honoraria - Incyte; Karyopharm Therapeutics; Novartis; Otsuka; Pfizer; Sunesis Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Novimmune (Inst); Pfizer (Inst); Sunesis Pharmaceuticals (Inst)
 
Koichi Takahashi
No Relationships to Disclose
 
Keyur Patel
Consulting or Advisory Role - Celgene
 
Rashmi Kanagal-Shamanna
Consulting or Advisory Role - Roche
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; ARIAD; BiolineRx; Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Teva (Inst)
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); Ariad (Inst); Astex Pharmaceuticals (Inst); BMS Brazil (Inst); Novartis (Inst); Pfizer (Inst)